23:05 , Jan 18, 2018 |  BC Innovations  |  Translation in Brief

A notch for tankyrase

New York University School of Medicine researchers have identified a multitude of tankyrase targets, including factors in the Notch and Wnt/β-catenin pathways, that offer new opportunities for tankyrase inhibitors in cancer. In a Nature Communications study...
19:08 , Jul 14, 2017 |  BC Week In Review  |  Company News

Eisai grants 2XOncology rights to 2X-121

Eisai Co. Ltd. (Tokyo:4523), Tokyo, Japan  2X Oncology Inc., Cambridge, Mass.  Business: Cancer  Eisai Co. Ltd. (Tokyo:4523) granted 2X Oncology Inc. (Cambridge, Mass.) exclusive, worldwide rights to develop and commercialize cancer candidate 2X-121 (previously E7449). The compound is...